BioLife Solutions establishes C&GT partnership with Seattle Children’s

Collaboration aims to prioritize best practices in fields of biopreservation and closed-system manufacturing, while improving children’s health

BioLife Solutions, Inc., a developer and supplier of bioproduction products and services for the cell and gene therapy (C&GT) industry, has formed an extended collaboration with Seattle Children’s Therapeutics, a venture at Seattle Children’s, with the goal of using technologies and therapies to tackle pediatric cancer and other diseases that affect children. The alliance will focus on establishing best practices in biopreservation and closed-system manufacturing, specifically with the introduction and integration of Sexton’s AF-500 for closed-system processing for cell therapy manufacturing and viral vector delivery that will be used in Seattle Children’s Therapeutics new lentiviral vector manufacturing facility called VectorWorks.

“This expanded collaboration is an exciting step for Seattle Children’s Therapeutics, as we work towards developing closed-system processes for cell therapy manufacturing,” says Matt Selley, director of good manufacturing practice (GMP) manufacturing at Seattle Children’s. “Lentiviral vector manufacturing is a critical component of the cell production process.”

Essentially, the goal is to use the AF-500 to initiate high throughput fill-finish of vector intermediates. As Seattle Children’s Therapeutics will be the end-user of the viral vector product, the workflow resulting from the collaboration will cover the movement of viral vectors from the point of packaging to the point of transduction and patient administration, when applicable.